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Abstract
Mendelian susceptibility to mycobacterial diseases (MSMD) are a spectrum of inherited disorders characterized by localized or
disseminated infections caused by atypical mycobacteria. Interferon-γ receptor 1 (IFNGR1) deficiency was the first identified
genetic disorder recognized as MSMD. Mutations in the genes encoding IFNGR1 can be recessive or dominant and cause
complete or partial receptor deficiency. We present the case of a 2½-year-old boy with a history of recurrent wheezing,
diagnosed with endobronchial mycobacterial infection. Immunological workup revealed a homozygous nonsense mutation in
the IFNGR1 gene, a novel mutation predicted in silico to cause complete IFNGR1 deficiency. This case demonstrates that (a)
Interferon-γ receptor deficiency can present resembling common disorders of the lung; (b) mycobacterial infections should
be suspected when parenchymal lung disease, hilar lymphadenopathy, and endobronchial disease are present; and (c) high
index of suspicion for immunodeficiency should be maintained in patients with disseminated nontubercular mycobacterial
infection.
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Introduction
Interferon-γ receptor 1 (IFNGR1) deficiency is a rare
immune deficiency characterized by selective susceptibility
to mycobacterial disease caused by genetic mutations in the
IFNGR1 gene.1 It comprises about 8% of patients in a group
of diseases referred collectively as to Mendelian susceptibility to mycobacterial disease (MSMD) syndromes.2 Patients
with MSMD feature genetic defects in genes encoding components of the interleukin (IL)-12/23-IFN-γ (interferon-γ)
axis, a critical mechanism in the clearance of intracellular
infections.3
The IFNGR1 gene maps to the chromosome 6q23.3. It is
composed of 22 868 base pairs arranged in 7 exons.4 On IFNγ binding, IFNGR1 chain induces the assembly of the IFN-γ
receptor (an IFNGR1 and IFNGR2 heterodimer) with subsequent activation of constitutively associated Janus kinases 1
and 2 (Jak1/2) and the downstream signal transducer and
activator of transcription 1 (STAT 1) mediated gene transcription.5 In the normal host, mycobacteria typically induce
IL-12 production by macrophages, which, in turn, trigger
IFN-γ production. In patients with IFNGR1 deficiency, macrophages fail to activate on IFN-γ stimulation from T- and
NK-cells, rendering the host susceptible to mycobacteria and
intramacrophagic microorganisms.2,5

Clinically, the characterization of IFNGR1 deficiency–
associated mutations translates in important differences in
disease severity and treatment approach. Complete autosomal recessive IFNGR1 deficiency is characterized by early
onset of disseminated life-threatening infections by lowvirulent mycobacteria, lack of response to IFN-γ cytokine
replacement therapy, and high mortality.6,7 To date hematopoietic stem cell transplant is the only curative therapy
available for these patients.6 Conversely, the clinical phenotype of the autosomal recessive partial and autosomal dominant forms is milder, usually with later onset, less severe
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Table 1. Summary of Laboratory Findingsa.
Test
White cell count
Hemoglobin
Platelets
Neutrophil count
Lymphocyte count
CD3 T cells
CD3+ CD4+ T cells
CD3+ CD8+ T cells
Maximum proliferation of PHA as % CD45
Maximum proliferation of PHA as % CD3

Patient’s Results

Age-Matched Control Range

14.73 K/uL
8.8 g/dL
282 K/uL
11.04 K/uL
2.81 K/uL
61%
31%
20%
58.9%
64.3%

5.5-17 K/uL
11.5-13.5 g/dL
172-440 K/uL
1.5-8.5 K/uL
2.0-9.5 K/uL
56% to 75%
28% to 47%
16% to 30%
≥49.9%
≥58.5%

a
Patient had mild chronic anemia with otherwise normal T and B blood cell counts and lymphocyte subpopulations. Lymphocyte proliferation to phytohemagluttinin (PHA) yielded normal values. Dihydrorhodamine test for chronic granulomatous disease showed normal oxidative burst.

Figure 1. Radiographic and bronchoscopic findings. (A) Mediastinal widening on initial chest radiograph. (B) Extensive mediastinal
lymphadenopathy, right main bronchus compression with right upper lobe collapse on chest computed tomography scan during hospital
admission. (C) Endobronchial masses found during bronchoscopy. Mycobacterium avium-intracellulare complex was isolated from
endobronchial granulation tissue.

infections, favorable response to IFN-γ and antibiotic therapy, and better survival rates without hematopoietic stem
cell transplant.7,8
In this article, we describe the case of a toddler boy with
a history of recurrent wheezing found to have an invasive
endobronchial mycobacterial infection. Genetic testing demonstrated a homozygous c.672 A>G nonsense mutation in
exon 5 of the IFNGR1 gene, a novel mutation predicted to
cause a stop codon and complete IFNGR1 deficiency. The
variant c.672G>A, detected in this patient, is novel and has
not been previously described in the literature. This case also
illustrates that IFNGR1 deficiency can present with common
respiratory symptoms and endobronchial disease in early
childhood.

Case Report
A 2½-year-old boy was admitted with a history of approximately 1 month of recurring fever, productive cough, and
intermittent episodes of wheezing and dyspnea. He had been
previously treated with azithromycin and cefdinir with only

partial improvement. His history was remarkable for recurrent episodes of wheezing and cough approximately every 4
to 6 weeks since the age of 15 months. He had been treated
with short courses of oral steroids and antibiotics intermittently with improvement. Otherwise he was a healthy welldeveloped boy. He was born at full term after an uneventful
pregnancy. His family history was unremarkable and there
was no history of consanguinity.
At the time of presentation, he was tachypneic and tachycardic with a normal pulsoximetry on exam. His chest exam
revealed bilateral wheezing. His abdomen was soft and nondistended with no visceromegaly. He had no clubbing. His
physical exam was otherwise unremarkable. Laboratory
analysis revealed mild anemia with a hemoglobin of 8.8 g/dL
(age-matched control range 11.5-13.5 g/dL). He had a white
cell count of 14.73 K/uL with normal absolute neutrophil and
lymphocyte counts (Table 1). Basic metabolic panel and
liver function tests were within normal limits.
Chest-X-ray revealed mediastinal widening (Figure 1A).
A computed tomography scan of the chest showed extensive
mediastinal lymphadenopathy with compression of the right
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Figure 2. (A) Sequence analysis identified a nonsense homozygous c.672G>A mutation in the IFNGR1 gene. This mutation is predicted
to produce a stop codon (TGA) with the resulting protein truncation. (B) Wild type DNA and protein sequences. In the normal protein,
the codon TGG encodes for a Tryptophan residue (W) at position 224 (p.Trp224x).

bronchus and collapse of the right upper lobe (Figure 1B). A
bronchoscopy revealed cauliflower-like endobronchial
masses with one occluding the right main bronchus (Figure
1C). Despite antibiotic therapy, the patient remained febrile
and with active respiratory symptoms. Because of a high suspicion of possible mycobacterial infection, empiric therapy
was initiated. Mycobacterium avium-intracellulare complex
was isolated from endobronchial granulation tissue, and
bronchoalveolar lavage fluid. After initiation of anti-mycobacterial therapy the patient improved clinically. He was discharged from the hospital on therapy with isoniazid,
ethambutol, azithromycin, and rifampicin. He remained afebrile and right upper lobe atelectasis had resolved at followup after 4 weeks of therapy.
An invasive infection by Mycobacterium avium-intracellulare complex raised the concern for an underlying immune
defect. Initial immunologic evaluation showed normal T, B,
and NK lymphocyte counts with CD4+ CD8+ subpopulations within the normal age-range. Dihydrorhodamine test
for chronic granulomatous disease showed normal oxidative
burst. Lymphocyte proliferation was preserved in response to
mitogen phytohemagluttinin. Genetic analysis demonstrated
a nonsense homozygous c.672G>A mutation in the IFNGR1

gene (Figure 2A). We used publicly available software to
simulate the potential deleterious effect of the found mutation.9,10 Our in silico modeling predicted the c.672G>A substitution to produce a stop codon at the end of exon 5 causing
an amino acid change (p.Trp224X) and truncation in the
extracellular domain of IFNGR1 likely to produce complete
deficiency (Figure 2B). Additional functional studies were
unavailable to us as patient transferred to another institution
for further care.

Discussion
We report a case of a 2½-year-old boy presenting with recurrent asthma-like symptoms and a mediastinal mass. Bilateral
endobronchial lesions and extensive lymphadenopathy secondary to an atypical mycobacterial infection were found.
Subsequently, an underlying primary immunodeficiency
associated with a novel nonsense homozygous mutation in
the IFNGR1 gene was characterized.
IFNGR1 deficiency can be inherited as an autosomal
recessive or an autosomal dominant trait. Functionally, the
defect may be partial or complete based on whether the
defective receptor is expressed on the cell surface and can
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Figure 3. In silico modeling and alignment of the wild type and mutated IFNGR1 extracellular domain. The red segment represents the
aligned 223 residues before the protein truncation. The purple segment corresponds to the unaligned residues of the wild protein after
the truncation at position 224. (Cn3D viewer—National Center for Biotechnology Information, The National Library of Medicine.)

bind IFN-γ.2,5,8 The autosomal recessive complete deficiency
is the rarest but most severe disease form. Approximately 32
individuals carrying 25 mutations have been diagnosed with
this variant worldwide.2 Most identified mutations to date
involve the extracellular domain of the receptor (exons 1 to
5), which usually results in complete absence of protein
expression.1,6,7 In contrast, mutations associated with autosomal dominant IFNGR1 deficiency have been found in parts
of the gene encoding for the intracellular segment of the
receptor (last part of exon 6 and exon 7).1,7 These mutations
produce defective intracellular signaling and receptor recycling but allow the expression of a partially functioning
receptor on the cell surface.5,8 These differences translate in
a milder clinical course, later onset, and response to IFN-γ
replacement, which along with antibiotic prophylaxis are the
first line of therapy.6-8

We describe a novel nonsense mutation in the IFNGR1 gene
that has not been previously described in association with a specific disease phenotype. Our in silico model predicted the
c.672G>A mutation present in this patient to produce a stop
codon at the end of exon 5 with the corresponding amino acid
change (p.Trp224X; Figure 2B). This mutation is located in the
area of the IFNGR1 gene encoding for the receptor’s extracellular domain, predicted to result in a truncated protein and in likely
complete IFNGR1 deficiency (Figure 2B and Figure 3). Of note,
in silico analyses, although informative in experimental settings,
should not replace appropriate testing for clinical purposes. In
this specific case, additional functional studies are needed to confirm the diagnosis of complete IFNGR1 deficiency. IFNGR1
staining by flow cytometry yields information on whether the
receptor is expressed on the cell surface.8 Additional suitable
options to evaluate IFNGR1 function include immunoblotting or
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flow cytometric evaluation of STAT1 phosphorylation after IFNα and IFN-γ stimulation.8 Establishing the residual protein function (partial vs absent) is essential in determining additional
therapeutic choices and long-term outcome.
In summary, this case highlights the need of excluding primary immune defects in patients presenting with low-virulent
nontubercular mycobacterial infections. In our case, a plain
chest radiograph provided the initial diagnostic clue to an atypical cause, underscoring the importance of baseline chest X-ray
evaluation of the wheezing child. This case reminds us that
causes of intrinsic and extrinsic airway compression should be
kept in the differential diagnosis when evaluating patients with
asthma-like symptoms. Although monogenic primary immunodeficiencies are rare, they should be fully explored once the initial clinical suspicion arises. Early diagnosis not only affects
patients’ prognosis but also proves definitive for other family
members who may need genetic counseling. Finally, given that
patients with complete and partial IFNGR1 deficiency require
radically different therapy, determining the functional effect of
genotyping findings in IFNGR1 deficiency cases is crucial and
can provide novel insights into the complex genetic mechanisms implicated in the control of IFN-γ receptor function.
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